Published on
May 26, 2026
- 12:00 GMT
MagVenture Receives FDA Clearance for Accelerated TMS Protocols, Expanding Flexibility for Clinics and Patients
ALPHARETTA, GA, UNITED STATES, May 26, 2026 /EINPresswire.com/ -- MagVenture®, a global leader in non-invasive neuromodulation technology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance for an expanded …
Distribution channels:
Healthcare & Pharmaceuticals Industry, Science
...
